An aerosolizable formulation comprised of a drug, a carrier and pH affectingcomponent is disclosed. The drug isdissolved in the formulation at a concentration above which it remains insolution at neutral pH. This increases the concentrationof the drug in solution making it possible to administer larger amounts ofdrug with the same or a smaller volume of formulation.When the formulation is aerosolized to small particles and inhaled into humanlungs in small volumes (e.g. 0.05 to 0.5 mL) thefluids in the lungs neutralize the formulation causing the drug to participateout of solution. This results in the drug being deliveredat a controlled rate below the rate at which drug is administered from aformulation initially at a neutral pH.
